Khanya Mona, Vuyokazi Ntlantsana, Andrew M Tomita, Saeeda Paruk
{"title":"Prevalence of cannabis use in people with psychosis in KwaZulu-Natal, South Africa.","authors":"Khanya Mona, Vuyokazi Ntlantsana, Andrew M Tomita, Saeeda Paruk","doi":"10.4102/sajpsychiatry.v28i0.1927","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is a high prevalence of cannabis use in patients with schizophrenia spectrum and other psychotic disorders, with comorbid cannabis use in this population being associated with poorer long-term outcomes.</p><p><strong>Aim: </strong>To determine the prevalence of cannabis use in patients with a schizophrenia spectrum and other psychotic disorders.</p><p><strong>Setting: </strong>The study was conducted at a psychiatric hospital in Durban, KwaZulu-Natal Province, South Africa.</p><p><strong>Methods: </strong>A review of clinical records of patients admitted to the hospital for the period, June 2018 to June 2020, was conducted.</p><p><strong>Results: </strong>A total of 370 clinical records were reviewed, of which 48.9% reported current and 51.1% lifetime cannabis use. Being male was significantly associated with current and lifetime cannabis use (OR = 4.90, 95% CI 2.49-9.62 and OR = 6.27, 95% CI 3.28-11.95, respectively). Current alcohol use was also associated with current cannabis use (CCU) (OR = 3.06, 95% CI 1.78-5.28), and age 45 years and older was associated with a lower odds of cannabis use (OR = 0.30, 95% CI 0.09-0.96). Forty-eight per cent of participants were admitted three or more times, and readmission was associated with cannabis use (<i>p</i> = 0.01). There was a lack of association between cannabis use, readmission and human immunodeficiency virus (HIV) status, after controlling for variables such as alcohol use and gender.</p><p><strong>Conclusion: </strong>Almost 50% of people admitted with schizophrenia spectrum and other psychotic disorders have comorbid current and lifetime cannabis use. There is a need for dual diagnosis units to address comorbid substance use in people with psychotic disorders, as it leads to poorer outcomes.</p><p><strong>Contribution: </strong>The study found that there is a high prevalence of cannabis use in people with psychosis. Therefore, it is imperative that we revise treatment programs in our psychiatric units and there is an urgent need for dual diagnosis programs that address substance use in this group of patients.</p>","PeriodicalId":520815,"journal":{"name":"The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa","volume":" ","pages":"1927"},"PeriodicalIF":1.3000,"publicationDate":"2022-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634825/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4102/sajpsychiatry.v28i0.1927","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Background: There is a high prevalence of cannabis use in patients with schizophrenia spectrum and other psychotic disorders, with comorbid cannabis use in this population being associated with poorer long-term outcomes.
Aim: To determine the prevalence of cannabis use in patients with a schizophrenia spectrum and other psychotic disorders.
Setting: The study was conducted at a psychiatric hospital in Durban, KwaZulu-Natal Province, South Africa.
Methods: A review of clinical records of patients admitted to the hospital for the period, June 2018 to June 2020, was conducted.
Results: A total of 370 clinical records were reviewed, of which 48.9% reported current and 51.1% lifetime cannabis use. Being male was significantly associated with current and lifetime cannabis use (OR = 4.90, 95% CI 2.49-9.62 and OR = 6.27, 95% CI 3.28-11.95, respectively). Current alcohol use was also associated with current cannabis use (CCU) (OR = 3.06, 95% CI 1.78-5.28), and age 45 years and older was associated with a lower odds of cannabis use (OR = 0.30, 95% CI 0.09-0.96). Forty-eight per cent of participants were admitted three or more times, and readmission was associated with cannabis use (p = 0.01). There was a lack of association between cannabis use, readmission and human immunodeficiency virus (HIV) status, after controlling for variables such as alcohol use and gender.
Conclusion: Almost 50% of people admitted with schizophrenia spectrum and other psychotic disorders have comorbid current and lifetime cannabis use. There is a need for dual diagnosis units to address comorbid substance use in people with psychotic disorders, as it leads to poorer outcomes.
Contribution: The study found that there is a high prevalence of cannabis use in people with psychosis. Therefore, it is imperative that we revise treatment programs in our psychiatric units and there is an urgent need for dual diagnosis programs that address substance use in this group of patients.
背景:在精神分裂症谱系和其他精神障碍患者中,大麻使用的患病率很高,在这一人群中,共病性大麻使用与较差的长期预后有关。目的:确定精神分裂症谱系和其他精神障碍患者大麻使用的患病率。环境:研究在南非夸祖鲁-纳塔尔省德班的一家精神病院进行。方法:回顾2018年6月至2020年6月住院患者的临床记录。结果:共审查了370份临床记录,其中48.9%报告当前使用大麻,51.1%报告终生使用大麻。男性与当前和终生使用大麻显著相关(OR = 4.90, 95% CI 2.49-9.62; OR = 6.27, 95% CI 3.28-11.95)。当前的酒精使用也与当前的大麻使用(CCU)相关(OR = 3.06, 95% CI 1.78-5.28),年龄45岁及以上与较低的大麻使用几率相关(OR = 0.30, 95% CI 0.09-0.96)。48%的参与者被入院三次或更多次,再入院与大麻使用有关(p = 0.01)。在控制了酒精使用和性别等变量之后,大麻使用、再入院和人类免疫缺陷病毒(艾滋病毒)状况之间缺乏关联。结论:几乎50%的精神分裂症谱系和其他精神障碍患者目前和终生使用大麻。需要双重诊断单元来解决精神障碍患者的共病物质使用问题,因为它会导致较差的结果。贡献:研究发现,精神病患者吸食大麻的比例很高。因此,我们有必要修改我们精神科的治疗方案,并且迫切需要双重诊断方案来解决这类患者的药物使用问题。